These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7095921)

  • 61. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The pharmacokinetics of Norpace.
    Karim A
    Angiology; 1975 Jan; 26(1 Pt 2):85-98. PubMed ID: 1090217
    [No Abstract]   [Full Text] [Related]  

  • 63. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Pharmacokinetic study of disopyramide in normal man].
    Mallein R; Rondelet J; Boucherat M; Ksavrelof M; Pignat M
    Therapie; 1978; 33(4):463-73. PubMed ID: 734626
    [No Abstract]   [Full Text] [Related]  

  • 66. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Disopyramide pharmacokinetics and metabolism: effect of inducers.
    Kapil RP; Axelson JE; Mansfield IL; Edwards DJ; McErlane B; Mason MA; Lalka D; Kerr CR
    Br J Clin Pharmacol; 1987 Dec; 24(6):781-91. PubMed ID: 3440098
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of ethanol intake on disopyramide elimination by healthy volunteers.
    Olsen H; Bredesen JE; Lunde PK
    Eur J Clin Pharmacol; 1983; 25(1):103-5. PubMed ID: 6617710
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
    Aitio ML; Vuorenmaa T
    Br J Clin Pharmacol; 1980 Feb; 9(2):149-52. PubMed ID: 7356902
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The pharmacokinetics and protein binding of disopyramide in pigs.
    Pedersen LE; Hermansen K; Olesen HP; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):282-8. PubMed ID: 3716823
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.
    Iisalo E; Aaltonen L
    Br J Clin Pharmacol; 1984 Mar; 17(3):325-9. PubMed ID: 6712865
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of enzyme induction on the metabolism of disopyramide in man.
    Aitio ML; Mansury L; Tala E; Haataja M; Aitio A
    Br J Clin Pharmacol; 1981 Mar; 11(3):279-85. PubMed ID: 7213529
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
    Haskins NJ; Waddell KA; Ford GC; Spalton PN; Walls CM; Forrest TJ; Palmer RF
    Biomed Mass Spectrom; 1980 Feb; 7(2):80-3. PubMed ID: 7407335
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Binding interaction between enantiomers of disopyramide and mono-N-dealkyldisopyramide on plasma protein.
    Takahashi H; Ogata H; Seki Y
    Drug Metab Dispos; 1991; 19(2):554-7. PubMed ID: 1676669
    [No Abstract]   [Full Text] [Related]  

  • 79. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data.
    Le Corre P; Ratanasavanh D; Chevanne F; Gibassier D; Sado P; Le Verge R; Guillouzo A
    Chirality; 1991; 3(5):405-11. PubMed ID: 1756095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.